Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 6871 AL 6885

Molecular interaction of stress granules with Tau and autophagy in Alzheimer's disease

Yu QY, Ye LQ, Li HL.

Neurochem Int. 2022 Jul;157:105342. doi: 10.1016/j.neuint.2022.105342. Epub 2022 Apr 21.

Targeting Insulin-Like Growth Factor-I in Management of Neurological Disorders

Makkar R, Behl T, Sehgal A, Singh S, Sharma N, Makeen HA, Albratty M, Alhazmi HA, Meraya AM.

Neurotox Res. 2022 Jun;40(3):874-883. doi: 10.1007/s12640-022-00513-7. Epub 2022 Apr 27.

Pathophysiological Role and Medicinal Chemistry of A(2A) Adenosine Receptor Antagonists in Alzheimer's Disease

Merighi S, Borea PA, Varani K, Vincenzi F, Travagli A, Nigro M, Pasquini S, Suresh RR, Kim SW, Volkow ND, Jacobson KA, Gessi S.

Molecules. 2022 Apr 21;27(9):2680. doi: 10.3390/molecules27092680.

Unmet needs in the diagnosis and treatment of Parkinson's disease psychosis and dementia-related psychosis

Sabbagh M, Small GW, Isaacson SH, Torres-Yaghi Y, Pagan F, Pahwa R.

Int J Psychiatry Clin Pract. 2023 Mar;27(1):69-81. doi: 10.1080/13651501.2022.2058406. Epub 2022 May 14.

The role of basket trials in drug development for neurodegenerative disorders

Cummings J, Montes A, Kamboj S, Cacho JF.

Alzheimers Res Ther. 2022 May 25;14(1):73. doi: 10.1186/s13195-022-01015-6.

Applications of Gold Nanoparticles in Brain Diseases across the Blood-Brain Barrier

Zhang J, Yang T, Huang W, Yu Y, Sun T.

Curr Med Chem. 2022;29(39):6063-6083. doi: 10.2174/0929867329666220527121943.

Therapeutic Potential of Semaglutide, a Newer GLP-1 Receptor Agonist, in Abating Obesity, Non-Alcoholic Steatohepatitis and Neurodegenerative diseases: A Narrative Review

Mahapatra MK, Karuppasamy M, Sahoo BM.

Pharm Res. 2022 Jun;39(6):1233-1248. doi: 10.1007/s11095-022-03302-1. Epub 2022 Jun 1.

Emerging therapeutic developments in neurodegenerative diseases: A clinical investigation

Kumar D, Md Ashraf G, Bilgrami AL, Imtaiyaz Hassan M.

Drug Discov Today. 2022 Oct;27(10):103305. doi: 10.1016/j.drudis.2022.06.005. Epub 2022 Jun 18.

Role of exosomes in the pathogenesis, diagnosis, and treatment of central nervous system diseases

Fan Y, Chen Z, Zhang M.

J Transl Med. 2022 Jun 27;20(1):291. doi: 10.1186/s12967-022-03493-6.

Icariin: A Potential Neuroprotective Agent in Alzheimer's Disease and Parkinson's Disease

Khezri MR, Ghasemnejad-Berenji M.

Neurochem Res. 2022 Oct;47(10):2954-2962. doi: 10.1007/s11064-022-03667-0. Epub 2022 Jul 8.

GLP-1 Receptor Agonists in Neurodegeneration: Neurovascular Unit in the Spotlight

Monti G, Gomes Moreira D, Richner M, Mutsaers HAM, Ferreira N, Jan A.

Cells. 2022 Jun 25;11(13):2023. doi: 10.3390/cells11132023.

Inosine in Neurodegenerative Diseases: From the Bench to the Bedside

Basile MS, Bramanti P, Mazzon E.

Molecules. 2022 Jul 21;27(14):4644. doi: 10.3390/molecules27144644.

Targeting endoplasmic reticulum stress using natural products in neurological disorders

Jangra A, Verma M, Kumar D, Chandrika, Rachamalla M, Dey A, Dua K, Jha SK, Ojha S, Alexiou A, Kumar D, Jha NK.

Neurosci Biobehav Rev. 2022 Oct;141:104818. doi: 10.1016/j.neubiorev.2022.104818. Epub 2022 Aug 5.

Targeting Oxidative Stress Mechanisms to Treat Alzheimer's and Parkinson's Disease: A Critical Review

Aborode AT, Pustake M, Awuah WA, Alwerdani M, Shah P, Yarlagadda R, Ahmad S, Silva Correia IF, Chandra A, Nansubuga EP, Abdul-Rahman T, Mehta A, Ali O, Amaka SO, Zuñiga YMH, Shkodina AD, Inya OC, Shen B, Alexiou A.

Oxid Med Cell Longev. 2022 Jul 31;2022:7934442. doi: 10.1155/2022/7934442. eCollection 2022.

A review of stem cell therapy: An emerging treatment for dementia in Alzheimer's and Parkinson's disease

Pradhan AU, Uwishema O, Onyeaka H, Adanur I, Dost B.

Brain Behav. 2022 Sep;12(9):e2740. doi: 10.1002/brb3.2740. Epub 2022 Aug 15.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias